Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BL&H acquires Trisenox licence for South Korea

This article was originally published in Scrip

Executive Summary

Nippon Shinyaku has sublicensed Cephalon's arsenic trioxide product Trisenox to BL&H for development and marketing in South Korea. The therapy, to which the Japanese firm acquired exclusive marketing rights in Japan, South Korea and Taiwan in late 2002, will be developed by BL&H for relapsed or refractory acute promyelocytic leukaemia (APL), its main indication. The disease affects around 250 people a year in South Korea, noted Nippon Shinyaku, which will receive undisclosed development milestones as part of the deal. Trisenox was launched for APL in Japan around four years ago.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts